The CRO scoreboard: reading the big five's Q1 2026 books

If book-to-bill forecasts CRO hiring, then reading all the public CROs together forecasts the whole industry. We pulled the Q1 2026 results for the five biggest names that report. The picture is not a clean recovery and not a clean slump. It is uneven, and the spread tells you more than any single number.

The board

Net book-to-bill for the quarter ended March 31, 2026, from each company's Q1 2026 results:

• ICON: 1.42, on net business wins of $2.88 billion and a $22.7 billion backlog
• Fortrea: 1.15 for the quarter, 1.05 trailing twelve months, its third straight quarter above 1.1
• IQVIA (R&D Solutions): 1.04 for the quarter, 1.11 trailing, with backlog up to $34.2 billion
• Charles River (preclinical DSA segment): 1.04, per management on the earnings call
• Medpace: 0.88, on $618 million of net awards, the one name below 1.0

What the spread means

Read top to bottom and you see a bifurcated market, not a uniform one. ICON and Fortrea are booking well ahead of what they are delivering, rebuilding backlog for future growth. IQVIA and Charles River are steady, booking a little more than they burn. Medpace, despite posting the fastest revenue growth in the group at over 26 percent, is the outlier: its book fell below 1.0 because cancellations rose and new bookings came in weak.

That divergence is the story. "CRO demand is recovering" is true in aggregate and false in the particular. Whether the tide is lifting your employer depends entirely on which of these you work for, which is exactly why the single industry headline is useless and the company-by-company number is not.

The caveats that matter

Do not rank these blindly. ICON's 1.42 benefits from a cancellation accounting change it made in late 2025, so it is not directly comparable to the others or to its own prior quarters. Charles River's 1.04 is for its preclinical segment only and came from the earnings call, not the filed release. Medpace books shorter, lumpier contracts, so its ratio swings hard quarter to quarter and one bad print is not a trend by itself. The numbers are real; the asterisks are too.

The signal underneath

The upstream driver of all of it is biotech funding, and it is thawing unevenly. IQVIA flagged emerging biopharma funding near $25 billion in the quarter, roughly double a year earlier, and a reopening IPO window. Charles River saw better funding but still-tepid early-stage demand. More biotech money eventually means more trials, which means more bookings, which eventually means more hiring. The recovery is real at the top of the funnel. It has not fully reached the staffing plans yet.

What the scoreboard cannot show

These ratios forecast demand for the work. They do not tell you what any of these employers pays, how it treats clinical staff, or whether it is cutting even while it books. A company can post a 1.15 book and run a layoff at the same time. The scoreboard tells you where the work is heading. What that means inside each company is the part only its workers can report. If you are at one of these five, add your datapoint, and turn the public number into a real one.